Introduction
Galactosialidosis is an inherited lysosomal storage disease transmitted as an autosomal recessive trait ( 1 ) . A genetic defect ofa multifunctional protein (protective protein) results in marked decreases in two lysosomal enzymes, f3-galactosidase (EC 3.2.1.23) and a neuraminidase (EC 3.2.1.18) (2, 3). It regulates their activities by forming a high molecular weight aggregate (2, [4] [5] [6] . Furthermore, the cDNA coding for this protein bears homology to that for yeast carboxypeptidase Y (7, 8) , and the NH2-terminal amino acid sequence ofits two subunits is identical with that of the enzyme esterase/deamidase purified from human platelets (9) . In fact, all these enzyme activities were markedly low or deficient in cultured lymphoblastoid cells and skin fibroblasts from galactosialidosis patients (10) (11) (12) . We concluded that it is a multifunctional protein with esterase, deamidase and carboxypeptidase activities, together with activities toward the other two enzyme molecules mentioned above.
The clinical manifestations of this disease are heterogeneous. The age of onset, phenotypic expression, severity, and prognosis are remarkably variable ( 1, 13, 14) . The incidence is high in the Japanese population, and most Japanese patients exhibit almost uniform neurosomatic manifestations in their teens or later. A small number of severe cases in early infancy have also been reported, with edema, ascites, skeletal dysplasia and cherry-red spots ( 13) .
Molecular analysis of Japanese adult patients revealed a common A-to-G substitution at position 3 of the 5' splice donor site of intron 7, causing skipping of exon 7 in protective protein mRNA (SpDEx7) (14, 15) . Clinically, homozygotes of this mutation showed less severe manifestations than compound heterozygotes, although individual signs and symptoms were almost indistinguishable from each other ( 14) . Two other different base substitutions have been reported, one in SpDEx7 compound heterozygote siblings of Japanese origin (16) and the other in cases of Italian or Canadian origin reported as "late-infantile type" ( 17) . There has been no report on any other mutations in SpDEx7 compound heterozygotes or in severe infantile-form patients. In this study, four additional base substitutions were identified in Japanese or French-German patients, and furthermore, the Y395C mutation mentioned in our previous report ( 16) was found to be common in Japanese patients. The expression products ofthese mutant cDNAs were analyzed in a transformed galactosialidosis cell line.
Methods
Patients. The clinical data for the patients in this study are summarized in Table I . They were unrelated, and described in previous reports ( 14, 16, 18, 19) . Patients 1 and 2 showed severe dysmorphism with hepatosplenomegaly, died of cardiopulmonary failure at 6 and 13 months of age, respectively, and were classified clinically as type I galactosialidosis cases. Patients 4-7 developed audiovisual disturbance or generalized convulsions before 15 years of age, and their subsequent clinical courses were more protracted, although sensorimotor dysfunction and intellectual deterioration were slowly progressive. They had gait disturbance of various degrees at the time of the last examination.
According to a clinical report ( 19) , patient 3 has been neurologically normal, although she has hepatosplenomegaly, stunted growth, and aortic insufficiency at 18 years of age. This clinical course is atypical, in spite of visceromegaly and slight dysmorphism of early onset, compared with the findings for the Japanese cases we analyzed clinically(l, 13, 14) .
Cell culture. Fibroblast strains or lymphoblastoid cell lines from normal Japanese subjects and six galactosialidosis fetus/patients were established in our laboratory. Clinical samples for DNA analysis were not available for patient 1, and so fibroblasts from an affected fetus of the next pregnancy were used for study. Lymphoblastoid cell lines from a galactosialidosis family ( 19) were obtained from the National Insti- (20) , and the transformed cell line, ASVGS-, was used for expression studies.
Preparation ofDNA, RNA andsynthetic oligonucleotides. Genomic DNA, total RNA and poly(A)' RNA were prepared as described previously ( 15) . Oligonucleotide primers for polymerase chain reaction (PCR) amplification of cDNA and genomic DNA were synthesized with the DNA Synthesizer (model 381; Applied Biosystems, Foster City, CA). Coordinates of the cDNA and amino acid sequences were numbered for the coding region starting from the initiation codon.
Amplification, sequencing, and restriction site analysis of cDNA and genomic DNA. Details of the procedures were reported in a previous paper ( 15) . The protective protein gene was PCR amplified in two overlapping portions, one directly from genomic DNA covering the 5' end ofthe open reading frame and the other from cDNA. Each of the products was then subcloned into pUC18 and sequenced. For confirmation ofthe mutation, the genomic DNA sequence comprising the base substitution was amplified. Restriction site analysis was performed with an appropriate enzyme ifthe mutation eliminated or created a restriction site. The PCR product without alteration ofthe restriction site was directly sequenced.
Construction of cDNA clone for expression of protective protein.
Protective protein cDNA (PPl 1) ( 15) was subcloned into the pUC 18
SalI site. This plasmid clone, pUC(PP), was digested with Apal and XbaI to remove the BsmI site in the 3' noncoding region, and then ligated with the SalI linker using a ligation kit (Takara Shuzo, Kyoto, Japan), after the digested fragment had been blunt ended with the Klenow fragment (21 ) . The resulting cDNA clones, pUC(PP) with the complete cDNA sequence and pUC(PPAX) with a partial deletion of the 3' noncoding region (starting from 1594), were digested with SalI, then subcloned into the XhoI site ofexpression vector pCAGGS (22) , and designated as pCAGGS(PP) and pCAGGS(PPAX), respectively. The mutant cDNA fragments in pUCl 8 were digested with BsmI and MscI, and then subcloned into pUC(PPAX). Finally, the plasmids containing mutant fragments were digested with SalI and subcloned into the XhoI site of pCAGGS. All mutant sequences were confirmed in the expression vector.
Transfection ofcDNA intoASVGS-J cells. ASVGS-l cells on 10-cm dishes were transfected with normal or mutant protective protein cDNA in expression vector pCAGGS (30 Ag plasmid DNA), by the calcium phosphate-mediated transfection method (21 ) . After 3 h, the transfected cells were treated with 3 ml of 15% glycerol for 60 s, cultured for 60 h, and then harvested by scraping. Carboxypeptidase, al-galactosidase, a-neuraminidase and f,-hexosaminidase activities were assayed ( 12, 23) , and the protein concentration was determined by the method of Bradford (24) .
Pulse-chase analysis. After transfection with cDNA and glycerol treatment, the cells on 6-cm dishes were cultured for 36 h, and pulse-labeled for 6 h in 5 ml of methionine/cysteine-free Dulbecco (25) , and protein A-Sepharose CL-4B (Pharmacia LKB, Uppsala, Sweden). The proteins were then separated by electrophoresis on a polyacrylamide gradient gel SDS-PAG Plate 4/20 (Daiichi Pure Chemicals, Tokyo, Japan). Radioactive bands were visualized by fluorography, after the gels had been treated with Amplify (Amersham, Buckinghamshire, UK) and dried.
Results
Mutation analysis ofprotective protein cDNA. Sequencing of cDNA fragments amplified at two overlapping regions revealed five different base substitutions (Tables I and II) . The splice junction mutation SpDEx7 was confirmed by the analytical methods described before (14, 15) . All patients were compound heterozygotes of two different mutations. Among them, Q49R, W65R, S9OL, and Y249N were the new mutations found in this study. Patients 4-7 had the common mutation, SpDEx7, and patients 2, 4, and 6 had another common mutation, Y395C. The mutation in the second allele was not identified for patient 2 or 3. The genotype of patient 1 was not directly determined in this study. However, her affected sibling (fetus) was analyzed, and two mutations, Y395C and S9OL, were found. The latter (S90L) comprised two base substitutions within the same translation codon, resulting in a single amino acid substitution. Each parent was probably heterozygous for one of these two mutations, but genotype analysis was not performed for them. We concluded that patient 1 also had the same genotype as the sibling fetus.
Sequencing and restriction site analysis ofgenomic DNA. For confirmation of the mutations described above, genomic DNA prepared from cultured cells was amplified in the region comprising each mutation, and the PCR product was subjected to further analysis. The W65R or Y249N mutation did not create or eliminate any known restriction site of the genomic sequence. The amplified DNA fragments were therefore directly sequenced, and the results for cDNA were confirmed (Fig. 1) .
The Y249N mutation was confirmed in one of the alleles for the cells from patient 3. Further analysis of the parents in this region revealed the same mutation in one of the father's alleles and a normal sequence in the mother. In this case, the second mutation was not identified.
The S9OL mutation eliminated an Alul restriction site. The 1 75-bp PCR product ofthe normal gene sequence was digested into a 144-bp fragment by the enzyme. The fetal sibling of patient 1 showed two bands, digested ( 144 bp) and undigested (175 bp) (Fig. 2 A) . The Q49R mutation in patient 5 eliminated a ScaI restriction site, giving both digested (233 bp) and undigested (295 bp) bands, which were consistent with the diagnosis of a heterozygote for this mutation (Fig. 2 B) . SnaBI site analysis was positive for the Y395C mutation as reported previously ( 16) .
Enzyme activities in cells transfected with mutant cDNA. Pulse-chase analysis. After transfection of normal cDNA and a 6-h pulse, the 54-kD precursor was synthesized and converted rapidly to mature proteins (32 and 20 kD) (Fig. 3) . The mutated cDNAs expressed the precursor that was detected as a band of apparently higher intensity than that for normal cDNA. The mature proteins did not appear in the cells transfected with mutant cDNAs except for those with Y249N. The Y249N expression of the mature protein was much lower than that of normal cDNA. The precursor was detected in the culture medium only for the normal and W65R cDNAs. The cells transfected with other cDNAs did not secrete an immunoprecipitable precursor into the medium (data not shown).
Discussion
Galactosialidosis is a disease with variable phenotypic expression that has been classified into a few clinical types. In a previous report, we divided Japanese galactosialidosis patients into two major groups ( 14) , type I with generalized and severe manifestations of neonatal or early infantile onset, and type II mainly with neurological manifestations of later onset. The latter was further divided into subtypes IIA (relatively severe) and IIB (relatively mild). The type II Japanese patients had a common gene mutation, SpDEx7. Subtype IIB corresponded roughly to homozygotes for this mutation and subtype IIA to compound heterozygotes ( 14) . The clinical course of patient 3 in this study did not conform to any clinical types for Japanese cases, and thus was tentatively designated as a variant type.
In this study, we identified five different base substitutions. (19) . This FrenchGerman case may represent a special variant ("late-infantile" form) with a protracted course, which is different from the sidase-protective protein complex. Electrophoresis was performed on a sodium dodecyl sulfate-polyacrylamide gradient gel. In this experiment, normal cDNA with partial deletion of the 3' noncoding region was used as a reference control, which expressed a normal amount of enzyme activity (see Table III ).
phenotypes of the Japanese patients. She was heterozygous for the Y249N mutation; her father was a healthy carrier, but Y249N was not detected in the mother. The Y249N mutation transiently expressed a small amount ofcarboxypeptidase catalytic activity, and slightly restored f3-galactosidase and a-neuraminidase activities. The second unknown mutation probably resulted in a marked decrease in mRNA, as we could not detect mRNA without the Y249N mutation in this patient. Taken together, we concluded that the protein produced by Y249N retained its function to some extent, protected against more destructive pathological lesions, and contributed to the mild phenotypic expression. There was no difference in enzyme activities, including that of carboxypeptidase, between the fibroblasts from patient 3 and those from other patients in this study (Shimmoto 
